• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    National Philanthropic Trust Welcomes Three Board Members

    1/3/24 9:30:00 AM ET
    $BANR
    $HLNE
    $OCGN
    Major Banks
    Finance
    Investment Managers
    Finance
    Get the next $BANR alert in real time by email

    Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth join the Board of Trustees at the largest national, independent donor-advised fund public charity

    National Philanthropic Trust (NPT), the largest national, independent public charity that manages donor-advised funds, and one of the leading grantmaking institutions in the U.S., is pleased to announce the appointment of Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth to its Board of Trustees.

    "As NPT continues to grow, innovate, and advance philanthropy around the world, we welcome these three accomplished professionals to our Board of Trustees," said Eileen Heisman, CEO of National Philanthropic Trust. "NPT is now the third largest grantmaking organization in the world. With esteemed careers in private market investing, technology, law, and philanthropy, Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth will make welcome additions to our board."

    Jeffrey Armbrister is an executive with more than 25 years of transaction-based investing and operational experience. He is the Chief Financial Officer of Hamilton Lane (NASDAQ:HLNE), a global private markets investment management firm.

    Armbrister previously served as the company's Global Head of Direct Equity Investments, where he was responsible for direction and oversight of the firm's direct equity and co-investment platform. His role included service on the boards of directors of companies in which Hamilton Lane invested on behalf of clients.

    Prior to joining Hamilton Lane, Armbrister served as Managing Director for Versa Capital Management, where he focused on making control-oriented, special situations, debt and equity investments in middle market companies across a variety of industries. While at Versa, he participated in all major investment functions, providing oversight for certain finance-related operational activities, including financial analysis and reporting and cash flow management for several portfolio companies.

    Prior to joining Versa, Armbrister was an Equity Research analyst at Oppenheimer + Close. He has also held private equity, venture capital, corporate development, and investment banking positions at Berwind Financial Group, Redleaf Group, ICG Commerce, and Wheat First Butcher Singer, respectively. He currently serves on the board of directors or similar bodies of several charitable organizations. Armbrister received his Bachelor of Arts in Economics from the University of Virginia.

    Lindy Benton-Moreno, an accomplished leader and sought-after speaker, has devoted her 30-year healthcare IT career to advancing technology and inspiring leaders. As an Executive Board Chair of Vyne, Benton-Moreno fueled the growth of a small dental company by establishing a thriving medical division.

    She was named by Health Data Management among the "Most Powerful Women in Healthcare IT" and recognized on Becker's "Women Power Players Health IT" list. As a Fellow at the Health Information and Management Systems Society, she engages with executive councils across health-related committees and industry associations.

    With a Master of Science from Florida State University, Benton-Moreno became a Distinguished Alumnus in Business and Industry, serving on the university's National Board of Directors as the university Alumni Association's National Director. Prior to entering healthcare IT, she pioneered the mainstreaming of 100+ children with disabilities into Florida's public schools and the sponsoring of scholarships for first-generation college students, an initiative close to her heart.

    Connie Collingsworth is an experienced board member with expertise in governance, risk management, executive compensation, and complex investments for publicly traded companies, private companies, and private equity funds. Her board experience includes leadership positions on public and private company boards as well as charitable organizations.

    Collingsworth's current board roles include Banner Corporation (NASDAQ:BANR) and Axxes Capital. She also serves as a Board Advisor to European private equity fund Planet First Partners, a Business Advisory Board Member to biotech company Ocugen (NASDAQ:OCGN), and a Strategic Advisor to venture fund LoudCapital.

    Collingsworth is the former Chief Operating Officer of the Bill & Melinda Gates Foundation, the largest private foundation in the world with over $65 billion in assets, distributing over $8.3 billion annually. During her 22-year tenure, she was responsible for managing and scaling the foundation's business operations globally. She also served as Chief Legal Officer, advising Bill Gates, Melinda French Gates, and Warren Buffett on governance, including creating the foundation's Governing Board. She was the architect of the foundation's IP philosophy and led the foundation's work in collaborating with for-profit companies, including big pharma and companies in the biotech and ed-tech sectors.

    Collingsworth holds a Master of Laws in International Business Studies from the University of Exeter, England, a Juris Doctorate from the University of Nebraska, and a Bachelor of Arts from Andrews University.

    About National Philanthropic Trust

    Founded in 1996, National Philanthropic Trust (NPT) is the largest national, independent public charity that manages donor-advised funds and one of the leading grantmaking institutions in the U.S. Since its founding, NPT has raised more than $49.8 billion in charitable funding and has made more than 640,000 grants exceeding $25.7 billion to nonprofits around the world. NPT annually publishes the Donor-Advised Fund Report, the sector's authority on the state of DAF philanthropy. Visit NPT's resource library to learn what you can do with a DAF and about NPT's impact investing options. More at NPTrust.org and NPTGivingPoint.org.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240103652385/en/

    Get the next $BANR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BANR
    $HLNE
    $OCGN

    CompanyDatePrice TargetRatingAnalyst
    Hamilton Lane Incorporated
    $HLNE
    5/15/2025Outperform → Perform
    Oppenheimer
    Banner Corporation
    $BANR
    4/21/2025$71.00Neutral → Buy
    Janney
    Hamilton Lane Incorporated
    $HLNE
    1/21/2025$186.00Perform → Outperform
    Oppenheimer
    Hamilton Lane Incorporated
    $HLNE
    1/6/2025$139.00Neutral → Sell
    Goldman
    Ocugen Inc.
    $OCGN
    10/15/2024$4.00Buy
    Maxim Group
    Hamilton Lane Incorporated
    $HLNE
    9/12/2024$156.00Equal Weight
    Wells Fargo
    Banner Corporation
    $BANR
    7/19/2024Buy → Neutral
    Janney
    Hamilton Lane Incorporated
    $HLNE
    4/11/2024$115.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $BANR
    $HLNE
    $OCGN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Hamilton Lane Incorporated

    SCHEDULE 13G - Hamilton Lane INC (0001433642) (Subject)

    8/13/25 4:05:09 PM ET
    $HLNE
    Investment Managers
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by Banner Corporation

    SCHEDULE 13G/A - BANNER CORP (0000946673) (Subject)

    8/12/25 10:34:25 AM ET
    $BANR
    Major Banks
    Finance

    Ocugen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Ocugen, Inc. (0001372299) (Filer)

    8/11/25 8:35:49 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BANR
    $HLNE
    $OCGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    12/2/24 4:15:25 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    11/26/24 4:50:10 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Co-Chief Executive Officer Delgado-Moreira Juan bought $105,950 worth of shares (525 units at $201.81) (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    11/13/24 4:31:06 PM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hamilton Lane downgraded by Oppenheimer

    Oppenheimer downgraded Hamilton Lane from Outperform to Perform

    5/15/25 8:08:14 AM ET
    $HLNE
    Investment Managers
    Finance

    Banner upgraded by Janney with a new price target

    Janney upgraded Banner from Neutral to Buy and set a new price target of $71.00

    4/21/25 8:28:02 AM ET
    $BANR
    Major Banks
    Finance

    Hamilton Lane upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Hamilton Lane from Perform to Outperform and set a new price target of $186.00

    1/21/25 7:49:57 AM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

    MALVERN, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reviewed the study design, endpoints and planned statistical analysis of the ongoing pivotal confirmatory OCU410ST Phase 2/3 GARDian3 clinical trial for Stargardt disease and provided acceptability of a single U.S.-based trial for submission of a Marketing Authorization Application (MAA). EMA provided this opinion based on safety and tolerability that OCU410ST demonstrated in the Phase 1 GARDian tria

    8/13/25 6:27:03 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

    MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with Janus Henderson Investors, a global asset management firm, for the purchase and sale of 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon

    8/12/25 3:45:31 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PennantPark Floating Rate Capital Ltd. Announces New Investment Venture with Hamilton Lane

    MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE:PFLT) today announced that it has formed PennantPark Senior Secured Loan Fund II, LLC ("PSSL II"), a joint venture with a fund managed by Hamilton Lane (NASDAQ:HLNE) ("HL"). PSSL II is expected to invest primarily in middle market loans consistent with PFLT's core origination and underwriting strategy. PFLT and HL have committed to provide a combined $200 million of notes and equity to the joint venture, with PFLT providing $150 million and HL providing $50 million. PSSL II intends to add a financing facility of $300 million which will enable the portfolio to grow to $500 million initiall

    8/11/25 4:05:00 PM ET
    $HLNE
    $PFLT
    Investment Managers
    Finance
    Finance: Consumer Services

    $BANR
    $HLNE
    $OCGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive VP, Banner Bank Costa James M was granted 4,646 shares, increasing direct ownership by 15% to 35,912 units (SEC Form 4)

    4 - BANNER CORP (0000946673) (Issuer)

    8/5/25 11:31:41 AM ET
    $BANR
    Major Banks
    Finance

    Director Herencia Roberto R was granted 64 shares, increasing direct ownership by 0.37% to 17,441 units (SEC Form 4)

    4 - BANNER CORP (0000946673) (Issuer)

    8/4/25 5:51:07 PM ET
    $BANR
    Major Banks
    Finance

    Director Boyer Ellen Rm was granted 64 shares, increasing direct ownership by 1% to 6,266 units (SEC Form 4)

    4 - BANNER CORP (0000946673) (Issuer)

    8/4/25 5:47:02 PM ET
    $BANR
    Major Banks
    Finance

    $BANR
    $HLNE
    $OCGN
    Leadership Updates

    Live Leadership Updates

    View All

    Cosette Pharmaceuticals Appoints Jeff Neubig as Vice President, Quality and Regulatory Affairs

    -- Experienced Industry Leader to drive Cosette's Best-in-Class Quality Organization and facilitate Regulatory Approvals -- Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630266171/en/Jeff Neubig, VP, Quality & Regulatory Affairs, Cosette Pharmaceuticals In this critical role, Jeff will lead Cosette's best-in-class quality and regulatory affairs organizations, maintaining the company's rigorous quality standards and further establishing Co

    6/30/25 8:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

    Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova's board, and the successful completion of a new round of growth equity capital. These developments support Grenova's strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company's future. "I

    4/23/25 8:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations

    Industry leader with 35+ years of experience in manufacturing operations and global supply chain excellence Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette's manufacturing, global supply chain, and operational strategy, ensuring efficiency, and supply continuity as the company continues its strong trajectory of growth and transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210366017/en/Senior Vice President, Operations (Photo

    2/10/25 8:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/13/24 9:56:40 PM ET
    $HLNE
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

    SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

    11/12/24 4:59:47 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/12/24 3:55:46 PM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    Financials

    Live finance-specific insights

    View All

    HAMILTON LANE INCORPORATED REPORTS FIRST QUARTER FISCAL 2026 RESULTS

    CONSHOHOCKEN, Pa., Aug. 5, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the first fiscal quarter ended June 30, 2025. The Company issued a full detailed presentation of its first quarter fiscal 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/ Dividend Hamilton Lane has declared a quarterly dividend of $0.54 per share of Class A common stock to record holders at the close of business on September 19, 2025 that will be paid on October 6, 2025. The target full-year dividend of $2.16 represents a 10% increase from the prior fiscal year

    8/5/25 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Ocugen Provides Business Update with Second Quarter 2025 Financial Results

    Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trialActively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial and on track for 2026 BLA filingOrthoCellix reverse merger intended to unlock the value of NeoCart/regenerative cell therapies and enable the Company to focus capital on modifier gene therapy platformSigned binding term sheet for exclusive Korean rights to OCU400 with upfront fees and near-term development milestone payments totaling up to $11 million MALVERN, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene

    8/1/25 8:25:22 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

    MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, August 1, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 9627149Webcast: Available on the events section of the

    7/17/25 6:30:16 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care